Better Health for All

Keros Therapeutics' core business is developing novel therapeutics for serious conditions like myelodysplastic syndromes (MDS), myelofibrosis, and pulmonary arterial hypertension (PAH), addressing high unmet medical needs.

Clinical trial data for KER-050 (elritercept) demonstrated durable transfusion independence, improved patient-reported fatigue, and spleen size reduction, with 50% of patients achieving an overall erythroid response. The company's entire business is devoted to health improvement through these therapeutics, and it derives no revenue from products with negative health impacts. However, the safety record shows notable concerns. For KER-050, four fatal treatment-emergent adverse events were reported in the MDS trial, though deemed unrelated to treatment. For KER-012 (cibotercept), dosing in two treatment arms was voluntarily halted due to unanticipated pericardial effusion adverse events. Keros notified investigators and regulatory authorities about the trial halt for KER-012, indicating a reactive safety approach. The decision to halt dosing was made in consultation with an independent Data Monitoring Committee and unblinded individuals at Keros, which suggests a basic level of ethical conduct in clinical trials, but the lack of further detail on trial ethics or participant protection limits a higher score.

Fair Pay & Worker Respect

In 2024, Keros Therapeutics reported a CEO to median employee pay ratio of 17:1, with the median employee compensation at $376,639.

Employee reviews on Glassdoor indicate an average rating of 3.6 out of 5 stars, which translates to approximately 72/100 for worker engagement. There is no public record of substantiated labor-law or human-rights violations. The company recently implemented a 45% reduction in force, resulting in 85 full-time employees remaining, with layoffs commencing after a legally required 60-day notice period.

Fair Trade & Ethical Sourcing

No information was found in the provided articles regarding Keros Therapeutics' fair trade and ethical sourcing practices.

Therefore, no KPIs could be scored against the rubric.

Honest & Fair Business

The provided articles do not contain specific, concrete data points for any of the KPIs related to Honest & Fair Business. There is no evidence regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage percentage, ESG controversy index, complaint resolution times, board conflict-free percentage, anti-corruption policies, or third-party verification.

While an audit firm and audit fees are mentioned, the percentage of audit coverage is not provided, nor is information on financial restatements.

Kind to Animals

Keros Therapeutics conducts preclinical studies using animal models, including mice, rats, and non-human primates, for multiple product candidates (KER-050, KER-047, KER-012).

These studies are performed to assess safety and predict therapeutic benefits, often due to legal and regulatory requirements. The company states it drafts IACUC protocols and aims to maintain the highest standards of animal welfare during these studies, including excellent animal handling skills. While specific annual animal testing volumes are not provided, the extensive list of preclinical studies across various animal types indicates significant involvement in animal testing. The company's financial reports confirm substantial research and development expenses, with animal testing being a core component of their drug development process.

No War, No Weapons

The provided articles for Keros Therapeutics, Inc. do not contain any specific, concrete data points or mentions related to arms manufacturing, military contracts, conflict facilitation, peacebuilding initiatives, dual-use technologies, sales to embargoed regimes, or any other metrics relevant to the 'No War, No Weapons' ethical value.

All articles explicitly state that no information was found or that the content is not applicable to these topics.

Planet-Friendly Business

The provided articles, primarily financial reports, corporate governance documents, and patent activity summaries, do not contain specific, quantitative data points for any of the 'Planet-Friendly Business' KPIs. While some articles mention general environmental policies or commitments, such as complying with environmental laws, minimizing environmental impacts, reducing waste, and minimizing the use of environmentally damaging substances, these are policy statements or commitments rather than evidence of concrete actions or measurable outcomes.

There is no information on emissions, renewable energy use, water consumption, waste diversion rates, green building certifications, or climate-related financial disclosures. The company's ESG Risk Score and Controversy Level are noted, but these are general assessments and do not provide the specific quantitative data required by the rubric's KPIs.

Safe & Smart Tech

The provided articles, which are primarily financial reports and regulatory filings, do not contain specific, concrete data points regarding Keros Therapeutics' performance on data protection, cybersecurity, or responsible AI. There is no explicit mention of data breaches, cybersecurity investments, privacy certifications, security training, encryption implementation, AI ethics governance, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, data minimization, regulatory compliance with privacy regulations, algorithmic harm remediation, or digital rights advocacy.

The reports explicitly state a lack of information on specific privacy/security certifications and compliance details, and no mention of data breaches or cybersecurity investments.